Booking Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Booking Holdings Inc trades at $212.21 (market cap $159.95B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Booking Holdings Inc is the larger of the two by market cap, and Booking Holdings Inc pays the higher dividend (0.79%). Which is the better fit depends on your goals.
| BKNG | REGN | |
|---|---|---|
Market Cap | $159.95B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $228.83 | $812.27 |
52-Week Low | $154.13 | $555.51 |
Enterprise Value | $163.43B | $77.90B |
Dividend Yield | 0.79% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
BKNG trades at $214.42, up 3.39% on strong Q2 2026 earnings beats, with bullish technical signals and a consensus price target of $239.31. Revenue growth accelerated to $26.92B in 2025, though net income dipped to $5.40B. The stock shows robust profitability with a 25.53% net margin and high ROE, but faces geopolitical and competitive pressures.
Outlook remains positive with resilient travel demand and AI integration driving efficiency, but risks include Middle East volatility and high debt levels. Analysts are overwhelmingly bullish with 64% buy ratings, supporting upside potential amid near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →